The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

Neurology

Volumn 53, Issue 3, 1999, Pages 448-456

  Fazekas, Franz ^a   Barkhof, F ^b   Filippi, M ⁱ   Grossman, R I ^c   Li, D K B ^d   McDonald, W I ^e   McFarland, H F ^f   Paty, D W ^d   Simon, J H ^g   Wolinsky, J S ^h   Miller, D H ^e  

^a UNIVERSITY OF GRAZ   (Austria)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

ⁱ Karl Franzens University ^*

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST ENHANCEMENT; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ECONOMIC ASPECT; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PREVALENCE; PRIORITY JOURNAL; REVIEW;

EID: 0033546636     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.3.448     Document Type: Review

References (72)

1. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
2. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
3. Filippi M, Horsfield MA, Ader HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998;43:499-506.
4. Paty DW, Asbury AK, Herndon RM, et al. Use of magnetic resonance imaging in the diagnosis of multiple sclerosis: policy statement. Neurology 1986;36:1575.
5. Kurtzke JF. Multiple sclerosis: what's in a name? Neurology 1988;38:309-316.
6. Thorpe JW, Kidd D, Moseley IF, et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 1996;119:709-714.
7. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988;38:1822-1825.
8. Horowitz AL, Kaplan RD, Grewe G, White RT, Salberg LM. The ovoid lesion: a new MR observation in patients with multiple sclerosis. AJNR Am J Neuroradiol 1989;10:303-305.
9. Gasperini C, Horsfield MA, Thorpe JW, et al. Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: relationship to clinical parameters. J Magn Reson Imaging 1996;6:580-584.
10. Zhao GJ, Li DKB, Cheng Y, Wang XY, Paty DW, and the UBC MS/MRI Research Group. Active multiple sclerosis lesions occur in dirty-appearing white matter as detected by serial magnetic resonance imaging. Ann Neurol 1998;44:465. Abstract.
11. Van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998;19:675-683.
12. van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlates of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-1288.
13. Van Waesberghe JH, Castelijns JA, Scheltens P, et al. Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis. J Magn Reson Imaging 1997; 15:155-162.
14. Gass A, Filippi M, Rodegher ME, Schwartz A, Comi G, Hennerici MG. Characteristics of chronic MS lesions in the cerebrum, brainstem, spinal cord, and optic nerve on T1-weighted MRI. Neurology 1998;50:548-550.
15. Offenbacher H, Fazekas F, Schmidt R, et al. Assessment of MRI criteria for a diagnosis of MS. Neurology 1993;43:905-909.
16. Simon JH, Holtas SL, Schiffer RB, et al. Corpus callosum and subcallosal-periventricular lesions in multiple sclerosis detection with MR. Radiology 1986;160:363-367.
17. Gean-Marton AD, Vezina LG, Marton KI, et al. Abnormal corpus callosum: a sensitive and specific indicator of multiple sclerosis. Radiology 1991;180:215-221.
18. Hashemi RH, Bradley WG, Chen DY, et al. Suspected multiple sclerosis: MR imaging with a thin-section fast FLAIR pulse sequence. Radiology 1995;196:505-510.
19. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999;122:17-26.
20. Catalaa I, Fulton JC, Zhang X, et al. MRI quantitation of gray matter involvement in multiple sclerosis and its correlation with disability measures and neurocognitive testing. Am J Neuroradiol 1999 (in press).
21. Miki Y, Grossman RI, Udupa JK, et al. Isolated U-fiber involvement in MS: preliminary observations. Neurology 1998; 50:1301-1306.
22. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069.
23. Filippi M, Yousry T, Baratti C, et al. Quantitative assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-echo with fast fluid-attenuated inversion recovery. Brain 1996;119:1349-1355.
24. Stevenson VL, Gawne-Cain ML, Barker GJ, Thompson AJ, Miller DH. Imaging of the spinal cord and brain in multiple sclerosis: a comparative study between fast FLAIR and fast spin echo. J Neurol 1997;244:119-124.
25. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094.
26. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63.
27. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetat dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489.
28. Barkhof F, Frequin STFM, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing/remitting multiple sclerosis patients treated with high dose intravenous methylprednisolone. Neurology 1992;42:63-67.
29. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43:2632-2637.
30. Campi A, Filippi M, Comi G, et al. Acute transverse myelopathy: spinal and cranial MRI with clinical follow-up. AJNR Am J Neuroradiol 1995;16:115-123.
31. Tartaglino LM, Friedman DP, Flanders AE, Lublin FD, Knobler RL, Liem M. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 1995;195:725-732.
32. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996;46:372-378.
33. Lycklama-a-Nijeholt GJ, Barkhof F, Scheltens P, et al. MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. AJNR Am J Neuroradiol 1997;18:1041-1048.
34. Gass A, Barker GJ, MacManus D, et al. High resolution magnetic resonance imaging of the anterior visual pathway in patients with optic neuropathies using fast spin echo and phased array local coils. J Neurol Neurosurg Psychiatry 1995; 58:562-569.
35. Miller DH, MacManus DG, Bartlett PA, Kapoor R, Morrissey SP, Moseley IF. Detection of optic nerve lesions in optic neuritis using frequency selective fat saturation sequences. Neuroradiology 1993;35:156-158.
36. Miller DH, Newton MR, van der Poel JC, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology 1988;38:175-179.
37. Beck RW, Arrington J, Murtagh FR, et al. Optic Neuritis Study Group. Brain magnetic resonance imaging in acute optic neuritis. Arch Neurol 1993;50:841-846.
38. Lee KH, Hashimoto SA, Hooge JP, et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1991;41:657-660.
39. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 1993;116:135-146.
40. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44:635-641.
41. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121:495-503.
42. Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24.
43. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;119: 2009-2019.
44. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-708.
45. Thompson AJ, Polman C, Miller DH, et al. Primary progressive multiple sclerosis: a review. Brain 1997;120:1085-1096.
46. Comi G, Filippi M, Martinelli V, et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 1995;132:222-227.
47. Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997;120:1149-1161.
48. Papadopoulos A, Gouliamos A, Trakadas S, et al. MRI in the investigation of patients with myelopathy thought to be due to multiple sclerosis. Neuroradiology 1995;37:384-387.
49. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683-1689.
50. Uhlenbrock D, Sehlen S. The value of T1-weighted images in the differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE). Neuroradiology 1989;3:203-212.
51. Liem MD, Gzesh DJ, Flanders AE. MRI and angiographic diagnosis of lupus cerebral vasculitis. Neuroradiology 1996;38: 134-136.
52. Provenzale JM, Heinz ER, Ortel TL, et al. Antiphospholipid antibodies in patients without systemic lupus erythematosus: neuroradiological findings. Radiology 1994;192:531-537.
53. Serdaroglu P. Behçet's disease and the nervous system. J Neurol 1998;245:197-205.
54. Kesselring J, Miller DH, Robb S, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990;113:291-320.
55. Mader I, Stock KW, Ettlin T, et al. Acute disseminated encephalomyelitis: MR and CT features. Am J Neuroradiol 1996; 17:104-109.
56. Harding AE, Sweeney MG, Miller DH, et al. Occurrence of multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 1992;115:979-989.
57. 12 deficiency. Neurology 1997;49:878-881.
58. Paty DW, Oger JJF, Kastrukoff LF, et al. Magnetic resonance imaging in the diagnosis of multiple sclerosis (MS): a prospective study of comparison with clinical evaluation, evoked potential, oligoclonal banding, and CT. Neurology 1988;38:180-185.
59. Thorpe JW, Kidd D, Miller DH, et al. Spinal cord MRI using multi-array coils and fast spin-echo. I. Findings in normal controls. Neurology 1993;43:2625-2631.
60. Junger SS, Stern BJ, Levine SR, Sipos E, Marti Masso JF. Intramedullary spinal sarcoidosis: clinical and magnetic resonance imaging characteristics. Neurology 1993;43:333-337.
61. Grossman RI, McGowan JC. Perspectives on multiple sclerosis. AJNR Am J Neuroradiol 1998;19:1251-1265.
62. Tas MW, Barkhof F, van Walderveen MAA, et al. The effect of gadolinium on the sensitivity and specificity of MR in the initial diagnosis of multiple sclerosis. AJNR Am J Neuroradiol 1995;16:259-264.
63. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766.
64. Simon JH. Contrast-enhanced MR imaging in the evaluation of treatment response and prediction of outcome in multiple sclerosis. J Magn Reson Imaging 1997;7:29-37.
65. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999;353:964-969.
66. Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 1997;120:1149-1161.
67. Hittmair K, Mallek R, Prayer D, Schindler EG, Kollegger H. Spinal cord lesions in patients with multiple sclerosis: comparison of MR pulse sequences. AJNR Am J Neuroradiol 1996; 17:1555-1565.
68. Filippi M, Yousry TA, Alkadhi H, Stehling M, Horsfield MA, Voltz R. Spinal cord MRI in multiple sclerosis with multicoil arrays: a comparison between fast spin echo and fast FLAIR. J Neurol Neurosurg Psychiatry 1996;61:632-635.
69. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996;46:373-378.
70. Warach S, Hajnal JV, Rovaris M, Filippi M. The role of techniques characterised by faster acquisition times in the evaluation of multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64(suppl 1):S59-S65.
71. Rovaris M, Yousry T, Calori G, Fesl G, Voltz R, Filippi M. Sensitivity and reproducibility of fast-FLAIR, FSE, and TGSE sequences for the MRI assessment of brain lesion load in multiple sclerosis: a preliminary study. J Neuroimaging 1997; 7:98-102.
72. O'Riordan JI, Losseff NA, Phatouros C, et al. Asymptomatic spinal cord lesions in clinically isolated optic nerve, brainstem and spinal cord syndromes suggestive of demyelination. J Neurol Neurosurg Psychiatry 1998;64:353-357.